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ABSTRACT: 
As part of a phase I clinical study, we assessed the pharmacokinetic properties of the 
combination of veliparib and temozolomide in patients with acute leukemias. Temozolomide is 
an oral alkylating agent that has activity in patients with acute leukemia. Veliparib is an oral Poly 
ADP Ribose Polymerase (PARP1 and PARP2) inhibitor that inhibits the base excision repair 
(BER) system, which results in increased temozolomide tumor toxicity and apoptosis. 
Methods: Plasma samples of 22 patients were collected at the University of Maryland 
Greenebaum Cancer Center. Adults 18 years and older with relapsed or refractory acute myeloid 
leukemia (AML) or pre-B- or T-cell acute lymphocytic leukemia (ALL) were enrolled in this 
study. The initial starting dose of temozolomide was 150 mg/m
2
 administered for 7 days in 
combination with veliparib at 20 mg twice a day. Dose escalation followed the standard 3+3 
design. The temozolomide dose would be escalated to 200 mg/m
2
. Subsequently, only veliparib 
would be escalated to 40, 80, 120, and 150 mg twice daily. Veliparib administration was 
continued for three additional days following the last temozolomide administration. Plasma 
samples were collected to evaluate the PK of temozolomide alone, veliparib alone and the 
combination of veliparib and temozolomide. Temozolomide was quantified by HPLC-UV and 
veliparib by LC-MS. 
Results: Veliparib decreased temozolomide peak concentration (Cmax) by 16% (P=0.015) and 
increased its apparent volume of distribution (Vd/F) by 17% (P=0.017). On the other hand, 
temozolomide increased veliparib Cmax by 33% (P=0.0002) and decreased its Cl/F by 26% 
(P=0.001). Veliparib exposure appears to be mostly linear with dose. Temozolomide clearance 
and volume of distribution in individual patients were not well-predicted by a published 
v 
population pharmacokinetics model (%RMSE=96%, 110.5%), but on average were similar 
(%MPE = 19%, 21.7%), respectively. 
Conclusion: Veliparib has a statistically significant effect on temozolomide Cmax and Cl/F, and 
temozolomide has a statistically significant effect on veliparib Cmax and Cl/F. The clinical 
relevance of these effects is likely small. 
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1.0  INTRODUCTION 
1.1 Background: 
Leukemia is a type of cancer that originates from bone marrow stem cells. In leukemic patients, 
stem cells produce abnormal white blood cells (leukemia cells), which do not die as normal cells. 
Leukemia can be classified into four types: chronic lymphocytic leukemia (CLL), chronic 
myeloid leukemia (CML), acute lymphocytic leukemia (ALL), and acute myeloid leukemia 
(AML).[1] 
Almost 90% of leukemia cases occur in adults 20 years and older. The most common types of 
leukemia in this population are CLL and AML. In children and teens, ALL is the most common 
leukemia accounting for approximately 75% of cases.[1] From 2005 to 2009, the leukemia 
incidence rate increased by 0.4% per year and leukemia death rates declined by 0.8% in men and 
1.4% in women. Total leukemia estimated deaths were 23,720 cases (Table 1). 
Current leukemia therapy includes different chemotherapy regimens. For acute myeloid 
leukemia (AML) and acute lymphocytic leukemia (ALL), treatment starts with an induction 
followed by a consolidation stage.  For AML, a widely used regimen for induction is cytarabine 
(ARA C) 100 to 200 mg/m
2
 with daunorubicin (an anthracycline) 45 to 80 mg/m
2
/d. The 
combination is given as 3 days of daunoribicin and 7 days of cytarabine (3 + 7 induction 
regimen). Other drugs used in AML include etoposide, mitoxantrone, and fludarabine. After 
2 
induction therapy is done, consolidation therapy starts to prevent relapse in patients who are in 
complete remission with the same drugs used in induction therapy [2, 3]. A major cause for 
treatment failure in this disease is resistance to cytarabine and daunorubicin [4]. 
 
 
Table 1. 2013 estimated new leukemia cases and deaths in the United States 
 
 Estimated new leukemia
 
(%) Estimated deaths (%) 
Acute lymphocytic leukemia (ALL) 6,070 (12.5%) 1,430 (6%) 
Chronic lymphocytic leukemia (CLL) 15,680 (32.3%) 4,580 (19.3%) 
Acute myeloid leukemia (AML) 14,590 (30%) 10,370 (43.7%) 
Chronic myeloid leukemia (CML) 5,920 (12.2%) 610 (2.6%) 
Others 6,350 (13.1%) 6,730 (28.4%) 
Total 48,610 (100%) 23,720 (100%) 
Adapted from Siegel et al Cancer statistics, 2013 
 
For ALL, induction therapy is done using vincristine, anthracycline, asparaginase, and a 
glucocorticoid. A tyrosine kinase inhibitor (imatinib) enhances the induction therapy of leukemia 
with the BCR-ABL fusion gene. In the consolidation stage, a commonly used regimen includes 
high dose methotrexate, mercaptopurine, asparaginase, and reinduction treatment [5]. 
Temozolomide is a 100 % bioavailable oral alkylating agent which is non-enzymatically 
converted at physiologic pH to its active product 5-(3-methyl)1-trizen-1-yl-imidazole-4-
carboxamide (MTIC). MTIC, which can also be metabolically derived from dacarbazine, 
alkylates DNA by methylating the N
7
 position of guanine (about 70%), the O
6
 position of 
guanine (about 5%), and the N
3
 position of adenine (about 9%)[6]. This methylation causes 
3 
single strand DNA breaks leading to growth arrest and apoptosis.  The repair is mainly 
performed by base excision repair (BER) for N
7
 guanine and N
3
 adenine, and methyl-guanine 
methyl-transferase (MGMT) for O
6
 guanine. DNA O
6
 guanine mismatch repair (MMR) is 
required for the cytotoxic effect of the O
6
 guanine lesion [7]. Temozolomide is approved for the 
treatment of brain tumors and it is also used in metastatic melanoma [8]. Significant activity of 
single agent temozolomide has been reported in patients with acute leukemia [9]. A recent study 
showed that temozolomide tumor toxicity was potentiated in mismatch repair deficient leukemia 
cells with low MGMT activity when a Poly ADP Ribose Polymerase inhibitor (PARPI) is used 
[10]. 
Poly ADP Ribose Polymerase (PARP) is a nuclear enzyme that is expressed in all cells. It is part 
of the base excision repair (BER) system. It recognizes DNA damage and facilitates its repair 
[11]. PARP adds ADP ribose units to DNA, histone and different DNA repair enzymes which 
affects many cellular processes[12]. PARP activity and expression is increased in human tumor 
cells when anticancer drugs are used, and is linked to chemotherapy resistance and prevention of 
apoptosis. Veliparib is an oral PARP-1 and PARP-2 inhibitor. 
Veliparib inhibits the BER pathway and prevents removal of N
3
- and N
7
 methyl adducts. This 
inhibition results in increased temozolomide tumor toxicity and apoptosis independent of 
MGMT or MMR status [10]. This combination is unique because it has a different molecular 
therapeutic approach than current methods. A phase I clinical trial was conducted to evaluate the 
feasibility, safety, and toxicity of administering veliparib in combination with temozolomide for 
the treatment of acute myeloid leukemia. 
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1.2 Purpose of the study: 
This study aims to evaluate the pharmacokinetic properties for the combination of veliparib and 
temozolomide. The first aim of this study is to evaluate alteration in both veliparib and 
temozolomide pharmacokinetics during co-administration. The second aim is to evaluate the 
dose-linearity of veliparib. The third aim is to compare temozolomide pharmacokinetics with 
historical controls. 
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2.0  METHODS: 
2.1 Patient selection: 
Samples were collected from 22 patients from the University of Maryland Marlene and Stewart 
Greenebaum Cancer Center. Patient enrolled in this study had to have: 
1) Relapsed or refractory acute myeloid leukemia (AML). 
2) Relapsed or refractory pre-B- or T-cell acute lymphocytic leukemia (ALL). 
3) Chronic Myeloid Leukemia (CML) in accelerated or blastic phase. 
4) AML arising in the setting of antecedent myelodysplasia (MDS) or myeloproliferative 
disorder (MPD). 
5) Therapy-related AML. 
6) Untreated AML or ALL in adults 60 years of age and older who are not candidates for 
induction chemotherapy due to poor-risk features. 
Patients should be 18 years old or older because there is not enough data about using this 
combination in children. Patients should be able to swallow pills because veliparib cannot be 
given by G-tube. Patients should have normal hepatic and renal function. Pregnant women were 
excluded because veliparib teratogenicity has not been established yet. 
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2.2 Study design: 
Veliparib was given orally as a single dose on day 1 to evaluate its pharmacokinetic properties. 
In all dose levels, a single dose of veliparib was given on day to allow for pharmacokinetics 
study. Subsequent doses of veliparib were given orally twice daily on days 4 through day 12. 
Temozolomide was given orally on day 3 through day 9. Veliparib dose was continued 3 days 
beyond temozolomide to allow leukemic cells to enter S phase without single-strand break (SSB) 
repair.  
Table 2. Dose Escalation Schedule 
Dose Level 
Dose 
 
Veliparib 
Day 1 (half the total daily dose) 
Days 4 through 12 
 
Temozolomide 
Days 3 through 9 
1A 20 mg twice a day 150 mg/m
2
/day 
1B 20 mg twice a day 200 mg/m
2
/day 
2 40 mg twice a day 200 mg/m
2
/day 
3 80 mg twice a day 200 mg/m
2
/day 
4 120 mg twice a day 200 mg/m
2
/day 
5 150 mg twice a day 200 mg/m
2
/day 
 
Doses were escalated according to Table 2 based on the presence of dose limiting toxicities 
(DLT). Toxicity was evaluated based on Version 4.0 of the National Cancer Institute (NCI) 
Common Terminology Criteria for Adverse Events (CTCAE).  Dose-limiting toxicity was 
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defined as any grade ≥4 drug-related non-hematologic toxicity, and any grade ≥3 drug-related 
non-hematologic toxicity that did not resolve to grade 2 within 48 hours with exception for 
infection, fever, febrile neutropenia, bleeding that are expected in this patient population. Also, 
any grade ≥3 neurotoxicity or grade ≥3 nephrotoxicity of any duration was considered a dose 
limiting toxicity. 
If there was no DLT in three patients, the dose was escalated to the next dose level. If one out of 
3 patients experienced DLT, then an additional three patients were added to the cohort. If no 
more patients experienced DLT, the dose was escalated to the next dose level. If more than one 
out of six experienced DLT, dose escalation was stopped and the dose level below this dose was 
expanded for consideration as the maximum tolerated dose.  
Plasma samples were collected on day 1, 3, and 8 before dosing and at  0.25, 0.5, 1, 1.5, 2, 4, 6, 
8, and 24 hours. Plasma samples taken on day 1 were used to evaluate the pharmacokinetic 
properties of veliparib when it was used alone. Plasma samples taken on day 3, after the first 
temozolomide dose, were used to evaluate the pharmacokinetic properties for temozolomide 
alone. The pharmacokinetic properties for both drugs when they were in combination were 
assessed by measuring their plasma concentrations from samples taken on day 8 (Figure 1). 
 
Figure 1. Veliparib and temozolomide dose regimen and drawn blood samples 
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2.3 Temozolomide HPLC-UV method: 
For temozolomide quantitation in plasma, we used an HPLC-UV assay described by Kim et al. 
and modified in our laboratory[13]. Mobile phase used was 0.1% aqueous acetic acid-acetonitrile 
(90:10, v/v). A 100 μL aliquot of plasma was placed into a 1.5 mL microcentrifuge tube 
containing 100 μL internal standard aqueous ethazolastone solution. 10 μL of 1 N HCl and 1 mL 
of ethyl acetate were added to each tube. Samples were vortexed for 10 minutes and then 
centrifuged for 5 minutes at 4500 x g at room temperature. Supernatants were transferred to 12 x 
75 mm glass tubes and evaporated to dryness under a gentle stream of nitrogen. The dried 
residues were re-suspended in 100 μL of mobile phase and sonicated for 2 minutes in a water 
bath. Finally, 20 μL of each sample were injected into HPLC system.  
2.4 Veliparib LC-MS method: 
For veliparib quantitation in plasma, we used an LC-MS assay developed and validated in our 
laboratory [14]. A gradient mobile phase was used in this assay. 0.1% (v/v) formic acid in 
acetonitrile was used as mobile phase solvent A, and 0.1% (v/v) formic acid in water was used as 
mobile phase solvent B (table 3). An aliquot of 200 μL of plasma was placed into a 1.5 mL 
microcentrifuge tube. 10 μL of internal standard, [D3]-veliparib in acetonitrile-water, and 1 mL 
ethyl acetate were added and mixed vigorously for 1 minute on a vortex genie set at 8. Then, the 
tube was centrifuged at 12,000 x g for 5 minutes at room temperature. After that, the resulting 
supernatants were transferred to 12 x 75 mm glass tube and evaporated to dryness under 
nitrogen. Dried residues were resuspended in 100 μL mobile phase and sonicated for 2 minutes 
9 
at room temperature. Finally, it was transferred to HPLC vials and 20 μL were injected into the 
LC-MS system.[14] 
 
Table 3. Gradient mobile phase for veliparib assay 
Time 
(min) 
Flow rate 
(mL/min) 
0.1% (v/v) formic acid in 
acetonitrile 
 (A%) 
0.1% (v/v) formic acid in water  
(B%) 
0 0.2 2 98 
10 0.2 30 70 
11 0.2 80 20 
14 0.3 80 20 
15 0.3 2 98 
25 0.3 2 98 
2.5 Pharmacokinetic analysis: 
The area under the curve (AUC) and the half-life of plasma temozolomide and veliparib 
concentrations were estimated by using non-compartment analysis with PK solution 2.0 (Summit 
Research Services). The time to reach the maximum concentration (Tmax) and the maximum 
plasma concentration (Cmax) were determined visually. We calculated the theoretical veliparib 
accumulation effect on day 8, based on its half-life and dosing interval using the following 
equation: 
  
 
   
  
    
    
   
                (1) 
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Where R is drug accumulation index,   is dose interval, and t½ is half-life [15].  
We used a population pharmacokinetic (POP-PK) method developed by Osterman et al to 
predict individual pharmacokinetic parameters of temozolomide clearance (Cl) and volume of 
distribution (Vd)[16]. Temozolomide clearance and volume of distribution are given by:  
 
Cl =10(1+ 0.2 *sex) + 4.2 * BSA              (2) 
 
Vd = 30.3 + 19.9 * BSA     (3) 
 
The predictive performance was evaluated by computation of the mean prediction error (MPE) 
(equation 3), which represents the bias, and the root mean square error (RMSE) (equation 4), 
which represents the precision. 
 
     
∑      
 
   
 
                (4) 
 
      √
∑     
      
 
                              (5) 
 
Where N is the number of pairs of estimated and reference parameters (Cl and Vd), and PEi is the 
relative prediction error for each pair difference between the estimated and reference value in 
natural logarithmic form [17].  
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2.6 Statistical analysis: 
We used the Wilcoxon signed ranks test to compare pharmacokinetic parameters when drugs 
were given alone and when they were combined. The dose linearity of veliparib was determined 
by linear regression of dose normalized peak concentration (Cmax/dose) and apparent clearance 
(Cl/F) versus dose using SPSS (version 21). A P-value less than 0.05 were considered 
statistically significant. 
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3.0  RESULTS 
Intense sampling plasma samples from 22 patients were analyzed to assess pharmacokinetic 
properties of temozolomide and veliparib when used alone or in combination. Temozolomide 
dose was escalated from 150 mg/m
2
/day to 200 mg/m
2
/day and then it was fixed for the 
following dose levels. Veliparib dose was escalated from 20 mg to 40, 80, 120, and 150 mg 
twice daily. The number of patients and their sex in each dose level are listed in Table 4. 
 
 
Table 4. Patient characteristics 
Dose level 
 1A 1B 2 3 4 5 
Number of patients 2 2 1 2 10 5 
Sex (men/ women) 1/1 1/1 0/1 1/1 7/3 2/3 
 
 
On day 1, 22 patients had complete temozolomide pharmacokinetic profile. On day 3, one 
patient profile was excluded due to a negative elimination half-life. On day 8, 7 patient profiles 
were excluded for both drugs due to missing data points. 
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The retention time for temozolomide and its internal standard was 2.7 min and 5 min, 
respectively. The calibration curve was linear over the concentration range of 0.1 to 20 μg/mL. 
Duplicate standard curves (0.1, 0.2, 0.5, 1, 2, 5, 10, and 20 μg/mL) on three different days were 
used to calculate the coefficient of variation (CV%) and the accuracy. The coefficient of 
variation range was between 3.3 and 8.4% and the accuracy was between -3.1 and 3.7%. 
Precision and accuracy were also evaluated with two quality control concentrations (QCs) for 
each level (0.2, 3, and 15 μg/mL) on three different days. Precision and accuracy were ≤ 8.2, and 
-5.52%, respectively. 
The retention time for veliparib and its internal standard was around 8 min. The calibration curve 
was linear over the concentration of 10 to 1,000 ng/mL. Duplicate standard curves (10, 30, 100, 
300, 500, 750, and 1000 ng/mL) on three different days were used to calculate precision (CV%) 
and accuracy. The coefficient of variation range was between 2.0 and 7.3%. The accuracy ranged 
between -1.5 and 2.4%. Precision and accuracy were also evaluated with two QCs for each level 
(20, 200, 800 ng/mL) on three different days and they were ≤ 13.3, and 4.8%, respectively. 
Temozolomide was taken starting day 3 through day 9.  Plasma samples were collected on day 3 
and day 8 to assess temozolomide pharmacokinetic alone and when combined with veliparib, 
respectively. Temozolomide average peak concentration (Cmax) for the 200 mg/m
2
 dose was 15.3 
µg/mL on day 3 and 13.07 µg/mL on day 8. Elimination half-life (t1/2) of temozolomide was 1.89 
hours on day 3 and 1.95 hours on day 8. Oral apparent clearance (Cl/F) was 9.14 L/h on day 3 
and 9.57 L/h on day 8. Apparent volume of distribution was 25.0 L on day 3 and 28.9 on day 8. 
Veliparib significantly decreased temozolomide Cmax by 16% (P = 0.015) and increased apparent 
volume of distribution by 17% (P = 0.017) (Table 5). There was extensive intra-individual 
temozolomide Cmax and AUC variability between day 3 and day 8 (Figure 2). 
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Table 5. Effect of veliparib on temozolomide pharmacokinetic properties for 200 mg/ m
2
 temozolomide 
dose, mean (±SD) 
Temozolomide parameter 
Day 3 
temozolomide 
alone 
Day 8 
temozolomide 
and veliparib 
Ratio 
Day8/ Day3 
P-value 
Cmax (µg/mL) 15.3 (5.43) 13.07 (4.3) 0.84 (0.23) 0.015 
Tmax (h) 0.94 (0.47) 1.25 (0.96) 1.18 (0.44) 0.398 
t1/2 (h) 1.89 (0.28) 1.95 (0.44) 1.06 (0.17) 0.636 
Cl/F (L/h) 9.14 (2.68) 9.57 (2.3) 1.11 (0.21) 0.085 
Vd/F (L) 25.0 (8.3) 28. 9 (12.0) 1.17 (0.33) 0.017 
 
 
Figure2. Temozolomide intra-individual variability area under the curve (AUC0-∞) and peak plasma 
concentration (Cmax) between day 3 and day 8 
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Table 6. Effect of temozolomide on veliparib pharmacokinetic properties, mean (±SD) 
Veliparib 
parameter 
Day 1 
veliparib alone 
Day 8 
temozolomide 
and veliparib 
Ratio 
Day8/ Day1 
Corrected 
Ratio 
P-value 
Cmax (µg/mL) Varies by dose* Varies by dose* 1.79(0.61) 1.33(0.38) 0.0002 
Tmax (h) 1.98 (1.39) 2.24 (1.15) 1.55 (1.04) - 0.517 
t1/2 (h) 7.79 (6.37) 7.72 (5.93) 1.24 (0.54) - 0.296 
Cl/F (L/h) 21.2 (9.5) 16.4 (4.7) 0.74 (0.16) - 0.001 
Vd/F (L) 205 (98) 175 (12) 0.91 (0.47) - 0.217 
* See appendix for detailed parameter listings. 
 
Veliparib was taken on day 1 as a single dose then starting from day 4 it was combined with 
temozolomide and continued for 8 days. Plasma samples were collected on day 1 and on day 8 to 
assess veliparib pharmacokinetics alone and when combined with temozolomide, respectively. 
On day 8, veliparib would have reached its steady state concentration. Veliparib Cmax on day 1 
and day 8 varied by dose level, with the veliparib dose ranging from 20 mg to 150 mg twice 
daily. Average elimination half-life (t1/2) of veliparib was 7.79 hours on day 1 and 7.72 hours on 
day 8. Oral apparent clearance (Cl/F) was 21.2 L/h on day 1 and 16.4 L/h in day 8. Apparent 
volume of distribution was 205 L on day 1 and 174 on day 8. Temozolomide significantly 
increased veliparib Cmax by 33% (P = 0.0002) and decreased apparent clearance by 26% (P = 
0.001) (Table 6). There was an extensive intra-individual variation for veliparib Cmax and AUC 
between day 1 and day 8. (Figure 3). 
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Figure 3. Veliparib intra-individual variability area under the curve (AUC) and peak plasma concentration 
(Cmax) between day 1 and day 8 
 
Change in bioavailability (F) can be the reason for the observed changes in CL/F and Vd/F. We 
tested for concordance in the changes in Cl/F and Vd/F within patients to better characterize 
whether these changes were caused by the impact on F. We calculated and plotted temozolomide 
Cl/F ratio on day 8 / day 3 relative to Vd/F ratio on day 8 / day 3.Also, we calculated and plotted 
veliparib Cl/F on day 8 / day 1 relative to Vd/F on day 8 / day 1 (figure 4). For temozolomide, 
Cl/F and Vd/F ratios per patient moved relatively in parallel for most patients. Ratio of Cl/F and 
Vd/F-ratio average was 0.96 with coefficient of variance (CV) 16.1%. The common factor in 
both parameters that we can contribute this effect to is bioavailability. Therefore, we can 
conclude from this result that veliparib may decrease temozolomide bioavailability which leads 
to changes in apparent pharmacokinetics parameters such as Cl/F and Vd/F.  
For veliparib, these effects were more variable. Even though the average ratio of Cl/F and Vd/F 
ratio was 0.95, the coefficient of variance was 39.8%, which is less supportive of an effect 
through bioavailability for veliparib. 
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Figure 4: Cl/F ratio relative to Vd/F ratio for temozolomide (A), and veliparib (B) 
Veliparib linearity was assessed using linear regression. A linear correlation was assessed by 
plotting veliparib dose-normalized peak concentration and clearance vs. its dose level on day 1 
and day 8. We excluded data from patients that received 150 mg/m
2
 temozolomide to eliminate 
any possible variation that could be caused by temozolomide on veliparib Cmax or Cl/F. The 
slope of the dose-normalized Cmax and Cl/F vs. dose was not statistically significant different 
from zero which is the expected slope for dose-normalized data under the assumption of linear 
pharmacokinetics (P = 0.561, and 0.245 for Cmax on day 1 and 8, respectively),  and (0.977, and 
0.059 for Cl/F on day 1 and 8, respectively) (figure 5). 
We used the algorithm developed by Osterman et al. to calculate the individual temozolomide 
clearance and volume of distribution values based on patient sex and body surface area (BSA). 
Then, we compared these values with our experimental results. The mean prediction errors 
(MPE) were 18.8%, 21.7% and root mean square errors (RMSE) were 95.7%, 110.5% for 
apparent clearance and apparent volume of distribution, respectively. Temozolomide apparent 
clearance and apparent volume of distribution relative to POP- PK prediction from literature are 
18 
shown in Figure 6. 
 
Figure 5. Scatterplots representing veliparib PK parameters as a function of dose: day 1 dose-normalized Cmax (A), 
day 8 dose-normalized Cmax (B),  day 1 clearance (C), day 8 clearance (D) 
 
 
 
 
Figure 6. Temozolomide predicted relative to observed apparent clearance (A), and  
apparent volume of distribution (B) 
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4.0  DISCUSSION 
Within a phase I clinical study, we assessed the pharmacokinetic properties for the combination 
of veliparib and temozolomide. Veliparib has a statistically significant but small effect on 
temozolomide Cmax and Vd/F.  In our study, the average temozolomide peak plasma 
concentration was decreased by 16% when veliparib was added. However, this effect has a minor 
effect on temozolomide AUC0-∞ with a 7% decrease on day 8 compared to day 3 (P=0.037). It 
was reported that temozolomide Cmax is decreased by food through a 9% decreased in the extent 
of absorption [18]. In this context, the decrease in the extent of absorption we observed was very 
similar. Temozolomide volume of distribution was significantly increased by 17% (P= 0.017) 
when veliparib was added. It is unlikely that the slight reduction in AUC will have any clinical 
significance. 
Veliparib Cmax was significantly increased by 79 % on day 8. However, this increase was inflated 
by the expected veliparib accumulation effect at the dosing schedule used. After we corrected for 
the veliparib accumulation effect on day 8, Cmax on day 8 was statistically significantly increased 
by 33% compared to day 1 (P=0.0002). Also, veliparib apparent clearance was statistically 
significant decreased by 26% on day 8. We believe that this increase in exposure will not have a 
critical clinical effect because veliparib is given up to 500 mg twice-daily dose, which is more 
than double the maximum dose in this study. 
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In vitro experiments which used recombinant human cytochrome P450 enzymes identified that 
the major cytochrome P450 veliparib metabolizing enzyme is CYP2D6 with minor contributions 
from CYP1A2, CYP2C19, and CYP3A4 [19]. Temozolomide is converted non-enzymatically at 
physiological pH to its active product MTIC, which is further degraded to 5-amino-imidazole-4-
carbox-amide (AIC), and a highly reactive methyldiazonium ion. Temozolomide and its product 
are finally excreted by the kidney [20]. There is no enzymatic involvement in the conversion of 
temozolomide to MTIC. Therefore, pharmacologic explanations that involve competitive 
inhibition for metabolic pathways are unlikely to be the reason for veliparib increased apparent 
clearance.  
Temozolomide Cl/F ratios on day 8 / day 3 relative to Vd/F ratios on day 8 / day 3 for within 
patients were relatively parallel for most patients. Veliparib may decrease temozolomide 
bioavailability which leads to changes in apparent pharmacokinetics parameters such as Cl/F and 
Vd/F. These effects were more variable with veliparib Cl/F and Vd/F ratios which is less 
supportive of an effect through bioavailability for veliparib. 
Alterations of metabolic pathways without direct competitive inhibition have been reported with 
other chemotherapeutic drugs such as paclitaxel and cisplatin. Paclitaxel is hepatically 
metabolized by cytochrome P 450 enzymes (CYP2C8 and CYP3A) whereas cisplatin major 
route of elimination is renal excretion. Studies showed that the treatment sequence of cisplatin 
followed by paclitaxel decreases paclitaxel clearance by 25% which lead to increased paclitaxel 
pharmacologic exposure by 33% resulting in higher paclitaxel patient toxicity. Therefore, it is 
recommended to start with paclitaxel followed by cisplatin to overcome this effect [21]. It is not 
necessary to sequence veliparib before temozolomide because it is unlikely that veliparib will 
cause any patient toxicity at the doses explored in the current study. 
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Veliparib linearity was assessed using linear regression. A linear correlation was assessed by 
plotting veliparib dose-normalized peak concentration and clearance vs. its dose level on day 1 
and day 8. Veliparib exposure appears to be linear with dose escalating.  
We used the algorithms developed by Osterman et al. to predict temozolomide CL/F and Vd/F 
on day 3, and evaluated the results by calculating MPE and RMSE. Results showed that these 
algorithms did not predict individual values for CL/F and Vd/F well (%RMSE = 96%, 110.5%), 
but the population average values were similar (%MPE= 19%, 21.7%, respectively). 
In conclusion, veliparib has a statistically significant effect on temozolomide Cmax and Vd/F. 
Temozolomide has a statistically significant effect on veliparib Cmax and Cl/F. These effects are 
likely not clinically relevant. This pharmacokinetic study showed that the combination of 
veliparib and temozolomide in leukemia patients has no relevant drug–drug interaction. 
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APPENDIX A 
TEMOZOLOMIDE DATA 
Patient 
number 
BSA 
(m2) 
Temozolomide 
Dose 
(mg/m2) 
SEX 
Veliparib 
 Dose 
(mg) 
t1/2   
day 3 
(h) 
t1/2  
day 8 
(h) 
C max  
day 3 
(µg/mL) 
C max  
day 8   
(µg/mL) 
Tmax  
day 3 
 (h) 
Tmax  
day 8 
(h) 
AUC(0-inf)  
day 3 
(µg*h/mL) 
AUC( 0-24)  
day 8 
(µg*h/mL) 
Real 
Cl  
day 3 
(L/h) 
predicted 
Cl  
day 3 
(L/h) 
Real Cl  
day 8 
(L/h) 
Real 
Vd  
day 3 
(L) 
predicted 
Vd  
day 3 
(L) 
Real Vd  
day 8 
(L) 
Remark 
1 2.4 150 M 20 1.8 1.6 10.2 8.3 1.0 1.0 27.4 25.6 13.1 13.3 14.1 35 36 33 - 
2 1.94 150 F 20 2.3 2.9 5.9 6.3 4.0 2.0 33.8 36.0 8.6 10.3 8.1 29 31 33 not enough data on day 8 
3 1.38 200 F 20 1.5 1.8 17.4 6.9 0.5 0.5 38.2 27.4 7.2 9.0 10.1 16 25 27 negative t1/2 on day 1 
4 2.23 200 M 20 2.3 3.0 8.7 9.6 1.0 1.0 36.2 31.9 12.3 12.9 13.9 40 35 61 - 
5 1.48 200 F 40 2.0 - 13.2 - 0.5 - 37.3 - 7.9 9.3 - 23 27 - no data on day 8 
6 1.89 200 M 80 1.9 1.9 6.8 7.4 1.0 1.5 31.8 31.6 11.9 12.2 12.0 32 31 33 - 
7 1.69 200 F 80 1.7 1.6 19.7 24.0 1.0 0.5 59.5 51.2 5.7 9.7 6.6 14 29 15 - 
8 1.9 200 M 120 1.4 2.0 33.0 14.8 1.0 1.5 71.6 47.5 5.3 12.2 8.0 11 31 23 - 
9 1.9 200 M 120 2.2 1.6 13.6 - 0.5 - 42.8 - 8.9 12.2 - 28 31 45 not enough data on day 8 
10 1.41 200 F 120 2.0 1.6 15.6 13.3 0.5 0.5 51.0 37.5 5.5 9.1 7.5 16 26 17 - 
11 2.01 200 M 120 1.6 1.5 17.0 15.5 1.5 2.0 43.4 50.6 9.3 12.5 7.9 21 33 17 - 
12 1.92 200 M 120 1.9 2.1 15.0 12.3 1.5 1.5 39.0 40.8 9.8 12.3 9.4 27 32 28 - 
13 2.38 200 M 120 2.0 2.2 17.4 11.4 1.5 2.0 57.9 47.1 8.2 13.4 10.1 24 37 32 - 
14 1.97 200 M 120 1.9 2.0 15.3 9.6 0.5 1.0 25.5 31.3 15.4 12.4 12.6 42 32 36 - 
15 1.86 200 F 120 1.5 1.7 18.0 15.4 0.3 0.3 40.4 47.0 9.2 10.1 7.9 20 31 20 - 
16 2.5 200 F 120 1.9 2.2 13.9 13.5 1.5 1.5 43.7 41.1 11.4 11.6 12.2 31 38 38 - 
17 1.77 200 M 120 2.0 - 9.3 - 0.5 - 32.2 - 11.0 11.9 - 32 30 - not enough data on day 8 
18 2.15 200 F 150 1.8 - 13.4 - 1.0 - 36.4 - 11.8 10.8 - 31 34 - no data on day 8 
19 1.81 200 F 150 1.6 1.6 14.7 14.5 1.0 0.5 44.1 35.6 8.2 10.0 10.2 19 30 23 - 
20 2.04 200 M 150 2.0 - 10.2 - 1.0 - 39.4 - 10.3 12.6 - 29 33 - not enough data on day 8 
21 2.11 200 F 150 2.6 2.8 14.6 10.5 2.0 4.0 74.9 68.0 5.6 10.7 6.2 21 34 25 not enough data to calculate day 8 t1/2 
22 2.03 200 M 150 2.0 1.6 19.3 17.4 0.5 0.5 53.2 45.3 7.6 12.5 9.0 22 33 21 - 
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APPENDIX B 
VELIPARIB DATA 
Patient 
number 
BSA 
(m2) 
Temozolomide 
Dose 
(mg/m2) 
SEX 
Veliparib 
Dose 
(mg) 
t1/2 
day 1 
(h) 
t1/2 
day 8 
(h) 
C max 
day 1 
(µg/mL) 
C max 
day 8 
(µg/mL) 
Tmax 
day 1 
(h) 
Tmax 
day 8 
(h) 
AUC(0-inf) 
day 1 
(µg*h/mL) 
AUC(0-12) 
day 8 
(ug*h/mL) 
Cl 
day 1 
(mL/h) 
Cl 
day 8 
(mL/h) 
Vd 
day 1 
(mL) 
Vd 
day 8 
(mL) 
Remark 
1 2.4 150 M 20 6.3 5.7 0.05 0.14 1.5 2.0 0.4 0.8 53078 25412 478655 208350 - 
2 1.94 150 F 20 5.7 - 0.12 - 4.0 - 1.2 - 16880 - 139564 - not enough data on day 8 
3 1.38 200 F 20 - 3.5 0.11 0.15 4.0 4.0 - 0.8 - 24362 - 123410 - 
4 2.23 200 M 20 5.6 7.7 0.08 0.14 0.5 1.0 0.7 1.1 29483 18803 237394 209634 - 
5 1.48 200 F 40 7.3 - 0.45 - 2.0 - 4.7 - 8572 - 89965 - no data on day 8 
6 1.89 200 M 80 8.9 6.9 0.26 0.69 1.5 2.0 3.1 4.6 25606 17435 327615 173414 - 
7 1.69 200 F 80 3.2 5.3 0.98 1.04 1.0 2.0 5.1 8.1 15635 9928 71453 75870 - 
8 1.9 200 M 120 7.1 5.3 0.86 0.87 1.0 4.0 6.9 7.4 17426 16156 179277 122534 - 
9 1.9 200 M 120 4.9 - 0.80 - 0.5 - 4.0 - 29835 - 212543 - not enough data on day 8 
10 1.41 200 F 120 3.8 4.8 1.08 1.50 1.5 1.5 6.4 9.2 18817 12997 101935 89923 - 
11 2.01 200 M 120 4.8 3.1 0.91 0.81 3.0 3.0 5.5 5.5 21824 21962 151669 99052 - 
12 1.92 200 M 120 5.4 5.2 0.74 1.74 1.5 2.0 5.7 10.9 21047 11018 163790 82576 - 
13 2.38 200 M 120 14.7 25.2 0.43 1.00 1.5 2.0 9.7 9.6 12375 12440 263085 452179 - 
14 1.97 200 M 120 4.1 6.1 0.89 1.34 2.0 1.5 5.9 8.8 20277 13640 120291 120250 - 
15 1.86 200 F 120 7.2 17.9 0.50 1.31 1.0 1.5 5.4 6.7 22053 17884 228719 462720 - 
16 2.5 200 F 120 6.1 5.1 0.49 0.83 6.0 4.0 5.0 7.3 24187 16494 212496 120537 - 
17 1.77 200 M 120 8.5 - 0.73 - 1.0 - 8.3 - 14377 - 176138 - not enough data on day 8 
18 2.15 200 F 150 8.9 - 0.61 - 4.0 - 6.8 - 22221 - 284486 - no data on day 8 
19 1.81 200 F 150 4.4 7.8 0.97 1.83 2.0 1.0 7.3 10.6 20463 14156 130701 158709 - 
20 2.04 200 M 150 33.2 - 1.19 1.30 1.0 0.5 19.7 - 7607 - 364129 - not enough data on day 8 
21 2.11 200 F 150 4.3 - 0.84 1.20 1.0 4.0 5.3 - 28326 - 176014 - not enough data to calculate day 8 t1/2 
22 2.03 200 M 150 9.3 6.2 0.85 1.90 2.0 2.0 9.8 11.2 15348 13416 205183 120153 - 
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